Idursulfase Beta

Summary

Idursulfase Beta (CHEMBL4297988) is a phase-3 clinical-stage enzyme (ATC A16AB16); indicated across 1 condition including mucopolysaccharidosis type 2.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Enzyme
• ATC class: A16AB16
• Indications: 1 condition
• Clinical trials: 3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297988
Name	Idursulfase Beta
Type	Enzyme
Max phase	3
ATC	A16AB16

Also known as: Hunterase, Idursulfasa beta, Idursulfase .beta., Idursulfase beta, IDURSULFASE BETA

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
mucopolysaccharidosis type 2	3	MONDO:0010674	MONDO:0010674

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01645189	PHASE3	COMPLETED	Safety and Efficacy of Hunterase
NCT07344376	PHASE3	COMPLETED	An Extension Study to Assess the Long-term Safety and Efficacy of Hunterase (Idursulfase Beta)
NCT02663024	PHASE2	UNKNOWN	Study of Idursulfase-beta (GC1111) in Hunter Syndrome

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).